OR WAIT 15 SECS
Agnes Shanley is senior editor of BioPharm International.
Good project management, budgeting, planning, and clear documentation are the only ways to prevent overruns and project failure.
Biopharmaceutical experts Stephen Perry, CEO of Kymanox, James Blackwell, principal consultant with The Windshire Group, and consultant Mike Ultee, share best practices and musts to avoid in biopharmaceutical technology transfer. Some crucial takeaways? Share all data (especially data on failed runs in the past), and include clear instructions for sampling. In addition, aim for reproducibility.
Download BioPharm International's